The Medical Letter on Drugs and Therapeutics
In Brief: Natalizumab (Tysabri) Withdrawn
Download PDF:   US English
Med Lett Drugs Ther. 2005 Mar 14;47(1204):21
 Select a term to see related articles  Leukoencephalopathy   Multiple sclerosis   natalizumab   Tysabri 

The February 14th issue of The Medical Letter reviewed natalizumab (Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in patients with multiple sclerosis. On February 28th, the FDA issued a Public Health Advisory announcing that marketing of the drug had been suspended because 2 patients who had been treated with natalizumab for more than 2 years had developed progressive multifocal leukoencephalopathy, a rare, often fatal disease (

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article